NCI-H1703Homo sapiens (Human)Cancer cell line

Also known as: NCIH1703, H-1703, H1703

🤖 AI SummaryBased on 14 publications

Quick Overview

Human lung cancer cell line with known mutations and drug sensitivity profiles.

Detailed Summary

The NCI-H1703 cell line is a human non-small cell lung cancer (NSCLC) cell line derived from a primary tumor. It is widely used in cancer research for studying molecular mechanisms of tumorigenesis, drug response, and genetic alterations. This cell line has been characterized for its mutations in key oncogenes and tumor suppressor genes, including TP53 and CDKN2A, and has been utilized in studies involving proteomic profiling, drug sensitivity screening, and identification of therapeutic targets. Research on NCI-H1703 has contributed to understanding the role of specific genetic alterations in cancer progression and treatment resistance.

Research Applications

Proteomic profilingDrug sensitivity screeningGenomic mutation analysisCancer progression studiesTherapeutic target identification

Key Characteristics

Mutations in TP53 and CDKN2ASensitivity to specific chemotherapeutic agentsUsed in high-throughput drug screeningCharacterized for protein expression profiles
Generated on 6/17/2025

Basic Information

Database IDCVCL_1490
SpeciesHomo sapiens (Human)
Tissue SourceLung[UBERON:UBERON_0002048]

Donor Information

Additional Information
  • Established from a 50 packs per year smoker (ATCC=CRL-5889)
Age54
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseLung squamous cell carcinoma
LineageLung
SubtypeLung Squamous Cell Carcinoma
OncoTree CodeLUSC

DepMap Information

Source TypeATCC
Source IDACH-000747_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53c.919+1G>T (IVS8+1G>T)HomozygousSplice donor mutationUnknown
MutationSimpleCDKN2Ap.Asp84Val (c.251A>T)Homozygous-Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
12
D10S1248
15
D12S391
18
D13S317
10
D16S539
10,12
D18S51
17,18
D19S433
13
D1S1656
15,17.3
D21S11
29
D22S1045
15,16
D2S1338
19,20
D2S441
10,14
D3S1358
16,17
D5S818
11
D7S820
10,12
D8S1179
11,13
DYS391
10
FGA
20
Penta D
10
Penta E
10,12
TH01
7
TPOX
8,11
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.

Jimenez C.R.

J. Proteomics 196:106-119(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Label-free quantitative proteomics and N-terminal analysis of human metastatic lung cancer cells.

Min H., Han D.-H., Kim Y., Cho J.Y., Jin J., Kim Y.

Mol. Cells 37:457-466(2014).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources